| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 30 | 2025 | 1558 | 3.040 |
Why?
|
| Genome-Wide Association Study | 23 | 2024 | 1837 | 2.910 |
Why?
|
| Polymorphism, Single Nucleotide | 31 | 2023 | 2854 | 2.910 |
Why?
|
| Selection, Genetic | 6 | 2024 | 168 | 1.980 |
Why?
|
| Genetic Predisposition to Disease | 27 | 2023 | 3359 | 1.960 |
Why?
|
| Genome, Human | 15 | 2020 | 1338 | 1.710 |
Why?
|
| Melanoma | 7 | 2024 | 953 | 1.680 |
Why?
|
| Skin Neoplasms | 7 | 2024 | 893 | 1.660 |
Why?
|
| Mutation, Missense | 13 | 2024 | 940 | 1.520 |
Why?
|
| Codon, Nonsense | 3 | 2022 | 144 | 1.430 |
Why?
|
| Prostatic Neoplasms | 11 | 2017 | 1602 | 1.390 |
Why?
|
| Gene Expression Profiling | 12 | 2025 | 1914 | 1.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2025 | 2125 | 1.130 |
Why?
|
| Neoplasms | 7 | 2020 | 2984 | 1.060 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 712 | 1.040 |
Why?
|
| Genes, Neoplasm | 2 | 2019 | 90 | 0.960 |
Why?
|
| Gene Frequency | 6 | 2022 | 752 | 0.890 |
Why?
|
| Quantitative Trait Loci | 4 | 2022 | 314 | 0.750 |
Why?
|
| X Chromosome | 1 | 2023 | 341 | 0.740 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 335 | 0.730 |
Why?
|
| Biomarkers, Tumor | 9 | 2025 | 1692 | 0.730 |
Why?
|
| Computational Biology | 6 | 2015 | 887 | 0.710 |
Why?
|
| Frameshift Mutation | 2 | 2019 | 201 | 0.690 |
Why?
|
| Scleroderma, Systemic | 2 | 2019 | 130 | 0.690 |
Why?
|
| Biological Evolution | 5 | 2015 | 254 | 0.640 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 368 | 0.610 |
Why?
|
| Genetic Variation | 6 | 2020 | 1596 | 0.600 |
Why?
|
| Mutation | 8 | 2024 | 6340 | 0.600 |
Why?
|
| Humans | 76 | 2025 | 133181 | 0.580 |
Why?
|
| Models, Statistical | 3 | 2019 | 499 | 0.520 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2020 | 1067 | 0.520 |
Why?
|
| RNA Splicing | 3 | 2014 | 254 | 0.480 |
Why?
|
| Blood | 1 | 2015 | 107 | 0.470 |
Why?
|
| Genomics | 2 | 2014 | 1677 | 0.460 |
Why?
|
| Gene Expression | 2 | 2018 | 1608 | 0.460 |
Why?
|
| Exons | 4 | 2014 | 825 | 0.450 |
Why?
|
| Alleles | 5 | 2020 | 1694 | 0.450 |
Why?
|
| Crossing Over, Genetic | 4 | 2001 | 55 | 0.440 |
Why?
|
| Genes, p53 | 2 | 2005 | 226 | 0.440 |
Why?
|
| Carcinogenesis | 1 | 2017 | 361 | 0.430 |
Why?
|
| Logistic Models | 7 | 2022 | 1861 | 0.410 |
Why?
|
| Male | 51 | 2025 | 65478 | 0.400 |
Why?
|
| Introns | 1 | 2014 | 317 | 0.400 |
Why?
|
| Environmental Exposure | 1 | 2015 | 236 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 15 | 4 | 2018 | 149 | 0.380 |
Why?
|
| Meiosis | 7 | 2001 | 116 | 0.380 |
Why?
|
| Algorithms | 5 | 2016 | 1730 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2024 | 782 | 0.350 |
Why?
|
| Recombination, Genetic | 4 | 2001 | 453 | 0.350 |
Why?
|
| Cryptorchidism | 4 | 2012 | 37 | 0.350 |
Why?
|
| Lung | 4 | 2023 | 1569 | 0.350 |
Why?
|
| Case-Control Studies | 15 | 2024 | 3408 | 0.350 |
Why?
|
| CpG Islands | 4 | 2023 | 347 | 0.350 |
Why?
|
| Genotype | 14 | 2016 | 2719 | 0.340 |
Why?
|
| Receptors, Nicotinic | 5 | 2012 | 139 | 0.340 |
Why?
|
| Oncogenes | 2 | 2022 | 181 | 0.340 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 707 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2019 | 111 | 0.330 |
Why?
|
| Genes, Essential | 1 | 2009 | 43 | 0.320 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 2751 | 0.310 |
Why?
|
| Genetics, Population | 3 | 2017 | 192 | 0.310 |
Why?
|
| Databases, Nucleic Acid | 2 | 2008 | 74 | 0.310 |
Why?
|
| Disease | 1 | 2010 | 131 | 0.310 |
Why?
|
| Membrane Proteins | 3 | 2019 | 1608 | 0.300 |
Why?
|
| DNA Methylation | 3 | 2024 | 1139 | 0.290 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 1363 | 0.280 |
Why?
|
| Chromosomes | 3 | 2000 | 160 | 0.270 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 43 | 0.270 |
Why?
|
| Smoking | 8 | 2024 | 943 | 0.260 |
Why?
|
| Organ Specificity | 2 | 2019 | 439 | 0.260 |
Why?
|
| Adenocarcinoma | 6 | 2020 | 1013 | 0.250 |
Why?
|
| Telomerase | 3 | 2019 | 169 | 0.250 |
Why?
|
| Homozygote | 4 | 2001 | 561 | 0.250 |
Why?
|
| Female | 33 | 2025 | 71395 | 0.240 |
Why?
|
| Survival Analysis | 2 | 2019 | 1583 | 0.230 |
Why?
|
| Point Mutation | 1 | 2006 | 358 | 0.220 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 3043 | 0.220 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2010 | 314 | 0.220 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2003 | 16 | 0.210 |
Why?
|
| Heterozygote | 4 | 2020 | 730 | 0.200 |
Why?
|
| Odds Ratio | 3 | 2022 | 1253 | 0.200 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2004 | 323 | 0.190 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 424 | 0.190 |
Why?
|
| Homeodomain Proteins | 2 | 2002 | 584 | 0.190 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 432 | 0.190 |
Why?
|
| Prognosis | 10 | 2024 | 5032 | 0.190 |
Why?
|
| Nucleotides | 1 | 2022 | 95 | 0.190 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2020 | 102 | 0.180 |
Why?
|
| DNA-Binding Proteins | 3 | 2022 | 2144 | 0.180 |
Why?
|
| Chromosome Mapping | 5 | 2012 | 1118 | 0.180 |
Why?
|
| Nigella sativa | 1 | 2020 | 1 | 0.180 |
Why?
|
| Trigonella | 1 | 2020 | 3 | 0.180 |
Why?
|
| Conserved Sequence | 1 | 2022 | 299 | 0.180 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 498 | 0.170 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 24 | 0.170 |
Why?
|
| Silent Mutation | 1 | 2020 | 3 | 0.170 |
Why?
|
| Proteins | 3 | 2018 | 1090 | 0.170 |
Why?
|
| Chromosome Inversion | 2 | 1991 | 77 | 0.170 |
Why?
|
| Risk Factors | 16 | 2020 | 10935 | 0.170 |
Why?
|
| Open Reading Frames | 2 | 2014 | 220 | 0.160 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2019 | 33 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 624 | 0.160 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 203 | 0.160 |
Why?
|
| Genetic Association Studies | 2 | 2022 | 860 | 0.160 |
Why?
|
| Middle Aged | 21 | 2024 | 28912 | 0.160 |
Why?
|
| Principal Component Analysis | 2 | 2017 | 158 | 0.150 |
Why?
|
| Mammals | 1 | 2000 | 281 | 0.150 |
Why?
|
| Phylogeny | 2 | 2018 | 780 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 1 | 2023 | 1420 | 0.150 |
Why?
|
| Simuliidae | 1 | 2018 | 4 | 0.150 |
Why?
|
| Polytene Chromosomes | 1 | 2018 | 3 | 0.150 |
Why?
|
| Mucins | 1 | 2019 | 77 | 0.150 |
Why?
|
| Karyotype | 1 | 2018 | 34 | 0.150 |
Why?
|
| Mutation Rate | 1 | 2018 | 72 | 0.150 |
Why?
|
| Risk | 1 | 2020 | 781 | 0.150 |
Why?
|
| Aged | 16 | 2024 | 21448 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2022 | 1462 | 0.140 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 161 | 0.140 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 18 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 216 | 0.130 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 317 | 0.130 |
Why?
|
| Autoimmunity | 1 | 2018 | 181 | 0.130 |
Why?
|
| Linear Models | 1 | 2019 | 719 | 0.130 |
Why?
|
| Testis | 3 | 2012 | 433 | 0.130 |
Why?
|
| Karyotyping | 6 | 2000 | 321 | 0.130 |
Why?
|
| Finasteride | 1 | 2016 | 20 | 0.120 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 702 | 0.120 |
Why?
|
| Mice | 12 | 2012 | 18928 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2014 | 708 | 0.120 |
Why?
|
| Phenotype | 7 | 2018 | 4574 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 442 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2022 | 945 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2012 | 32 | 0.110 |
Why?
|
| Models, Genetic | 4 | 2008 | 786 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 822 | 0.110 |
Why?
|
| Prostatectomy | 1 | 2016 | 356 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 260 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 631 | 0.110 |
Why?
|
| Animals | 17 | 2022 | 36184 | 0.110 |
Why?
|
| Inflammation | 2 | 2012 | 1556 | 0.110 |
Why?
|
| Alternative Splicing | 2 | 2007 | 378 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 2650 | 0.100 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2012 | 5 | 0.100 |
Why?
|
| DNA Transposable Elements | 1 | 1993 | 189 | 0.100 |
Why?
|
| Life Style | 1 | 2015 | 457 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2012 | 142 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 318 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2015 | 361 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 234 | 0.090 |
Why?
|
| Cocarcinogenesis | 1 | 2011 | 16 | 0.090 |
Why?
|
| Animal Feed | 2 | 2022 | 83 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 181 | 0.090 |
Why?
|
| Chickens | 2 | 2022 | 639 | 0.090 |
Why?
|
| Software | 1 | 2016 | 732 | 0.090 |
Why?
|
| Ligaments | 1 | 2010 | 21 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2012 | 436 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 222 | 0.090 |
Why?
|
| Laparoscopy | 1 | 2016 | 520 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 87 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2092 | 0.080 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2010 | 88 | 0.080 |
Why?
|
| Genotyping Techniques | 2 | 2020 | 110 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 2521 | 0.080 |
Why?
|
| beta Catenin | 1 | 2010 | 231 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 1151 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2010 | 214 | 0.070 |
Why?
|
| Genes, Overlapping | 1 | 2008 | 7 | 0.070 |
Why?
|
| Survival Rate | 2 | 2012 | 2204 | 0.070 |
Why?
|
| 5' Untranslated Regions | 1 | 2008 | 59 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 741 | 0.070 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 180 | 0.070 |
Why?
|
| Disease Progression | 2 | 2013 | 2242 | 0.070 |
Why?
|
| Europe | 2 | 2019 | 373 | 0.070 |
Why?
|
| Sex Factors | 1 | 2011 | 1350 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 7137 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2286 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2012 | 4915 | 0.060 |
Why?
|
| Spermatocytes | 1 | 1986 | 24 | 0.060 |
Why?
|
| Diet | 3 | 2022 | 1170 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 638 | 0.060 |
Why?
|
| DNA, Recombinant | 1 | 2006 | 106 | 0.060 |
Why?
|
| PAX6 Transcription Factor | 2 | 2002 | 39 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2010 | 446 | 0.060 |
Why?
|
| Paired Box Transcription Factors | 2 | 2002 | 77 | 0.060 |
Why?
|
| Adult | 8 | 2024 | 31616 | 0.060 |
Why?
|
| Insulin | 1 | 2010 | 1244 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2002 | 1325 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2139 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 813 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 500 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2002 | 432 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 236 | 0.060 |
Why?
|
| Genetic Markers | 3 | 1993 | 623 | 0.060 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2004 | 19 | 0.060 |
Why?
|
| Eye Proteins | 2 | 2002 | 234 | 0.050 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 591 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2004 | 64 | 0.050 |
Why?
|
| Smokers | 1 | 2024 | 45 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3169 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2003 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2003 | 52 | 0.050 |
Why?
|
| Haplotypes | 3 | 2011 | 545 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1467 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2002 | 3960 | 0.050 |
Why?
|
| Mentha piperita | 1 | 2022 | 12 | 0.050 |
Why?
|
| Relaxin | 1 | 2002 | 15 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1757 | 0.050 |
Why?
|
| Prebiotics | 1 | 2022 | 29 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 269 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 123 | 0.050 |
Why?
|
| Folic Acid | 1 | 2004 | 291 | 0.050 |
Why?
|
| DNA Primers | 1 | 2002 | 656 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17526 | 0.040 |
Why?
|
| Gene Deletion | 3 | 2012 | 806 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2023 | 5191 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 415 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 911 | 0.040 |
Why?
|
| Powders | 1 | 2020 | 28 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 1986 | 604 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2012 | 256 | 0.040 |
Why?
|
| Eye | 1 | 2002 | 237 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2002 | 871 | 0.040 |
Why?
|
| Jews | 1 | 2020 | 33 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 155 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3794 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 625 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 757 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 504 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 541 | 0.040 |
Why?
|
| Black Sea | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 562 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2022 | 487 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2018 | 55 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 767 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 699 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2003 | 1071 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 622 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2020 | 505 | 0.030 |
Why?
|
| Young Adult | 3 | 2018 | 9921 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 1340 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2022 | 1031 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2020 | 685 | 0.030 |
Why?
|
| HapMap Project | 1 | 2016 | 13 | 0.030 |
Why?
|
| Pedigree | 1 | 2020 | 1729 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2876 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 398 | 0.030 |
Why?
|
| Transgenes | 2 | 2010 | 344 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 426 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 306 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 67 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 310 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 301 | 0.030 |
Why?
|
| Chromosome Banding | 2 | 1991 | 140 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3411 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 718 | 0.030 |
Why?
|
| Probability | 1 | 2013 | 327 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 328 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 467 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4823 | 0.020 |
Why?
|
| Texas | 2 | 2012 | 3664 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2016 | 519 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1660 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 314 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1993 | 808 | 0.020 |
Why?
|
| Sperm Count | 1 | 2012 | 93 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2011 | 20 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 135 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 32 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 436 | 0.020 |
Why?
|
| Activin Receptors, Type I | 1 | 2011 | 35 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2002 | 400 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 627 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 463 | 0.020 |
Why?
|
| Muscle Development | 1 | 2010 | 77 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 20549 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2016 | 700 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2002 | 787 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 963 | 0.020 |
Why?
|
| Actins | 1 | 2012 | 342 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1990 | 176 | 0.020 |
Why?
|
| Genes | 1 | 2010 | 448 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2954 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 841 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1582 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1928 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 277 | 0.020 |
Why?
|
| Infertility, Male | 1 | 2012 | 296 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2559 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 719 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 825 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 118 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2002 | 2784 | 0.020 |
Why?
|
| Heart Failure | 1 | 2020 | 2428 | 0.020 |
Why?
|
| 11-Hydroxycorticosteroids | 1 | 1986 | 1 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2008 | 480 | 0.020 |
Why?
|
| Testosterone | 1 | 2012 | 620 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 1048 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1986 | 317 | 0.020 |
Why?
|
| Aneuploidy | 1 | 1986 | 144 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 1530 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 1041 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8627 | 0.010 |
Why?
|
| Registries | 1 | 2012 | 1582 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 3153 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5435 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 2026 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13235 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 127 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2004 | 252 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 136 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 304 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 14865 | 0.010 |
Why?
|
| Glycine | 1 | 2002 | 172 | 0.010 |
Why?
|
| Plasmids | 1 | 2002 | 529 | 0.010 |
Why?
|
| Pigmentation | 1 | 2001 | 36 | 0.010 |
Why?
|
| Contig Mapping | 1 | 2001 | 56 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 1100 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 500 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 1095 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 1136 | 0.010 |
Why?
|
| Infertility | 1 | 2001 | 82 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 669 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 13094 | 0.010 |
Why?
|
| Spermatogenesis | 1 | 2001 | 177 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 689 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 781 | 0.010 |
Why?
|
| Peptides | 1 | 2002 | 863 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1851 | 0.010 |
Why?
|
| Child | 1 | 2018 | 25847 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1675 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 4754 | 0.010 |
Why?
|
| Siberia | 1 | 1988 | 4 | 0.000 |
Why?
|
| Animals, Wild | 1 | 1988 | 29 | 0.000 |
Why?
|